(ANSA) - MILAN, MARCH 15 - Roche will acquire GenMarkDiagnostics, a US company operating in the molecular diagnostics sector, through a public purchase offer at a price of 24.05 dollars (20.16 euros) for a total value of the transaction equal to 1.8 billion dollars (1.5 billion euros). This is what is required by an agreement signed by the two companies.
The price incorporates a premium of approximately 43% over the closing price of GenMark's shares on February 10, 2021.
The merger agreement was unanimously approved by the boards of directors of GenMark and Roche. (HANDLE).
